drugset / Trial / NCT00407381

The Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-2) Study

NCT00407381

RandomizedParallel-groupOpen-labelTreatment

Summary

This study is being done to see if the investigational drug Ranibizumab (RBZ) given by injection into the eye, is safe and effective to use in people with diabetic macular edema (DME). The investigators want to compare RBZ to laser treatment which is the current standard way to treat DME. RBZ blocks a growth factor that is thought to be involved in the formation of abnormal blood vessels that cause loss of vision in patients with DME.

Timeline

Start
2006-12
Primary completion
2010-08
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranibizumab Monoclonal antibody 0.05 ml Intravitreal
Subject Ranibizumab Monoclonal antibody 0.5 mg Intravitreal